Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.33 |
| ▸ | CDK2 | P24941 | 12/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 12/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90845 | 0.77 | HCAR2 (0.42) | NPY5RHCAR2CCNA2CDK2CCNA1 | |
| SCHEMBL90870 | 0.76 | DRD4 (0.48) | DRD2DRD3CCNA2CDK2CCNA1 | |
| SCHEMBL91023 | 0.74 | MKNK1 (0.57) | DRD2DRD3 | |
| SCHEMBL91033 | 0.72 | MKNK1 (0.42) | NPY5RCCNA2CDK2CCNA1 | |
| SCHEMBL91005 | 0.72 | MEN1 (0.61) | CCNA2CDK2CCNA1 | |
| SCHEMBL91004 | 0.72 | DRD4 (0.57) | DRD2DRD3CCNA2CDK2CCNA1 | |
| SCHEMBL90995 | 0.72 | MEN1 (0.46) | DRD2DRD3CCNA2CDK2CCNA1 | |
| SCHEMBL90977 | 0.71 | MEN1 (0.45) | — | |
| SCHEMBL90871 | 0.70 | KMT2A (0.44) | DRD2DRD3HCAR2CCNA2CDK2 | |
| SCHEMBL90983 | 0.70 | DRD2 (0.50) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | NPY5R 1/4885DRD2 351/4885HTR1D 287/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | NPY5R 1/4885DRD2 351/4885HTR1D 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.